To ask Her Majesty's Government what is their assessment of the efficacy of current standard forms of treatment for idiopathic pulmonary fibrosis.
The department has made no assessment of the efficacy of current standard forms of treatment for idiopathic pulmonary fibrosis (IPF). It is the responsibility of local National Health Service organisations to make decisions on the commissioning and funding of any health care treatments for NHS patients.
The National Institute for Health and Clinical Excellence (NICE) is developing technology appraisal guidance on the use of pirfenidone (Esbriet) for the treatment of patients with mild to moderate IPF. NICE issued initial draft guidance for consultation on